PMID- 33463213
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 2373-9878 (Electronic)
IS  - 2373-9878 (Linking)
VI  - 6
IP  - 1
DP  - 2020 Jan 13
TI  - Chemically Modified Natural Polymer-Based Theranostic Nanomedicines: Are They the 
      Golden Gate toward a de Novo Clinical Approach against Cancer?
PG  - 134-166
LID - 10.1021/acsbiomaterials.9b00802 [doi]
AB  - It is an unquestionable fact that cancer, also called malignancy, has or will 
      soon become the major global health care problem with an increasing incidence 
      worldwide. Conventional treatment approaches (e.g., radiation or chemotherapy) 
      treat both cancerous and surrounding normal tissues simultaneously, which leads 
      to a poor therapeutic effect on tumors and severe toxic side effects on healthy 
      tissues. Considering these thematic issues, the design and development of more 
      efficient treatment approaches is one of the most important demands of health 
      care in the near future. In this context, the emergence of nanotechnology opens 
      new opportunities for addressing the issues of conventional drug delivery systems 
      (DDSs) for cancer therapy. Theranostic nanomedicines are indebted to the advent 
      of nanotechnology and were introduced by Funkhouser in 2002. These nanomedicines 
      are the newest DDSs that combine diagnostic and therapeutic properties into a 
      single platform. Theranostic nanomedicines are generally composed of targeting 
      agents, diagnostic tracers, effective drug(s), and biomaterial(s) as the matrix 
      to the formulation. Among these, biomaterials have a pivotal role in theranostic 
      nanomedicines due to their direct influence on the system effectiveness. In this 
      context, natural polymers can be considered as potential candidates, mainly due 
      to their inherent physicochemical as well as biological advantages. However, 
      natural polymers have some drawbacks, which can be addressed through the chemical 
      modification approach. In this review, we will highlight the recent progress in 
      the development of theranostic nanomedicines based on chemically modified natural 
      polymers as well as research prospects for the future.
FAU - Jaymand, Mehdi
AU  - Jaymand M
AUID- ORCID: 0000-0003-1416-4543
AD  - Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah 
      University of Medical Sciences, Kermanshah 6715847141, Iran.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20191211
PL  - United States
TA  - ACS Biomater Sci Eng
JT  - ACS biomaterials science & engineering
JID - 101654670
RN  - 0 (Polymers)
SB  - IM
MH  - *Drug Delivery Systems
MH  - Humans
MH  - Nanomedicine
MH  - *Neoplasms/drug therapy
MH  - Polymers
MH  - *Theranostic Nanomedicine
OTO - NOTNLM
OT  - cancer therapy
OT  - chemical modification
OT  - natural polymers
OT  - theranostic nanomedicines
EDAT- 2021/01/20 06:00
MHDA- 2021/04/29 06:00
CRDT- 2021/01/19 08:39
PHST- 2021/01/19 08:39 [entrez]
PHST- 2021/01/20 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
AID - 10.1021/acsbiomaterials.9b00802 [doi]
PST - ppublish
SO  - ACS Biomater Sci Eng. 2020 Jan 13;6(1):134-166. doi: 
      10.1021/acsbiomaterials.9b00802. Epub 2019 Dec 11.